Ramipril After Transcatheter Aortic Valve Implantation in Patients Without Reduced Ejection Fraction: The RASTAVI...

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Pharmacology

Background:

• Patients undergoing transcatheter aortic valve implantation (TAVI) face ongoing risks of heart failure, arrhythmias, and mortality.
• Renin-angiotensin system inhibitors are being investigated for their potential benefits in post-TAVI patients.

Purpose of the Study:

• To investigate the efficacy of ramipril in improving outcomes for patients with aortic stenosis following TAVI.
• To assess the impact of ramipril on cardiac mortality, heart failure readmissions, and stroke.

Main Methods:

• The PROBE trial was a multicenter study randomizing 186 patients post-TAVI to ramipril or standard care.
• The primary endpoint was a composite of cardiac mortality, heart failure readmission, and stroke at 1 year.
• Secondary endpoints included left ventricular remodeling and fibrosis assessed by cardiac MRI.

Main Results:

• The primary endpoint occurred in 10.6% of the ramipril group versus 12% in the control group (P=0.776).
• Ramipril significantly reduced heart failure readmissions (3.2% vs. 10.9%, P=0.040) but showed no difference in cardiac mortality.
• Ramipril improved left ventricular remodeling, with greater reductions in ventricular volumes compared to the control group.

Conclusions:

• Ramipril administration post-TAVI in patients with preserved ejection fraction did not meet the primary composite endpoint.
• Ramipril was associated with a significant reduction in heart failure readmissions at 1-year follow-up.
• Ramipril demonstrated benefits in left ventricular remodeling after TAVI.